managing director
Jack Weinstein
JACK WEINSTEIN, Managing Director, is one of Avalon’s healthcare/life sciences subject matter experts. Jack brings over 40 years of wide-ranging executive management expertise, including as a CFO, investment banker and consultant in the biopharmaceutical and life sciences industries. He has extensive experience in finance and healthcare investment banking, corporate finance and business development, as well as FDA regulatory and intellectual property strategies. He has successfully completed a variety of corporate finance transactions, including public and private financings, as well as mergers and acquisitions.
Jack was the Chief Executive Officer of Relief Therapeutics Holding AG (SIX:RLF.SW), a biopharmaceutical company. From August 2020 until December 2022, he was Relief’s Chief Financial Officer and Treasurer, raising over $80 million, in-licensing two products and completing two acquisitions. In addition to his investment banking experience, Jack has previously served as Head of Healthcare for three other firms. At Catalyst Pharmaceuticals (Nasdaq: CPRX), a specialty pharmaceutical company, Jack was CFO, VP of Business Development and Treasurer. As part of CPRX’s senior management, he in‐licensed two prescription drugs, and raised over $35 million in private and public equity financing, including a full‐blown IPO. Jack brings additional insights based on skills gained as an operator and equity investor. As a General Partner of a private equity fund, he raised capital for the fund, evaluated investments, served as a Board of Director member and actively assisted portfolio companies develop and implement strategic acquisitions and growth plans. As an operating executive, he restructured a division of a healthcare services and consulting company to make it a viable independent entity. Jack earned his MBA from the Harvard Business School and graduated from the University of Miami with a BM degree, magna cum laude. Jack also holds FINRA Series 79 and 63 Licenses.